Bowen Acquisition CORP Form 4 insider transactions

Bowen Acquisition Corp has announced a second amendment to its merger agreement with Shenzhen Qianzhi BioTechnology Co. Ltd., extending the deadline for consummation to December 14, 2025.

Harraden Circle Investments, a 10% owner of Bowen Acquisition Corp, sold 5,432 ordinary shares at a weighted-average price of $12.1174 on May 12, 2025.

Harraden Circle Investments, LLC reports the sale of 2,800 ordinary shares of Bowen Acquisition Corp at a weighted average price of $12.0353.

Harraden Circle Investments, a 10% owner and director of Bowen Acquisition Corp, sold 5,376 ordinary shares at a weighted average price of $12.0764 on May 8, 2025, leaving them with indirect ownership of 494,206 shares.

Harraden Circle Investments, a significant shareholder in Bowen Acquisition Corp (BOWN), has decreased its holdings through a series of transactions on May 7, 2025.

Harraden Circle Investments, a significant shareholder in Bowen Acquisition Corp, has reported the sale of a portion of its ordinary shares.

Harraden Circle Investments, a significant shareholder in Bowen Acquisition Corp (BOWN), has sold a portion of its ordinary shares, reducing its holdings.

Harraden Circle Investments, a 10% owner of Bowen Acquisition Corp (BOWN), has reported the sale of ordinary shares across multiple transactions on April 23, 2025, resulting in a slight decrease in their beneficial ownership.

Harraden Circle Investments, a 10% owner and director in Bowen Acquisition Corp, reports selling shares at prices ranging from approximately $20 to $27 on April 22, 2025, reducing its indirect holdings.

Bowen Acquisition Corp. has amended its merger agreement with Shenzhen Qianzhi BioTechnology, extending the deadline for completion to July 14, 2025.

Bowen Acquisition Corp. enters into a Prepaid Forward Purchase Agreement (FPA) with Harraden Circle Investments to potentially maximize funds retained following its business combination with Qianzhi Group Holding.

Bowen Acquisition Corp. has successfully extended its deadline to complete a business combination by up to three months, now targeting April 14, 2025.

Bowen Acquisition Corp clarifies shareholder redemption rights related to the upcoming Business Combination Approval Meeting and Extension Approval Meeting.

Bowen Acquisition Corp has entered into a subscription agreement for a $5 million private investment in public equity (PIPE) offering, contingent on the closing of its business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.

Bowen Acquisition Corp obtained a $690,000 loan to extend the deadline for completing its initial business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. to January 14, 2025.

Bowen Holding LP, a 10% owner of Bowen Acquisition Corp, reported the transfer of 30,000 ordinary shares to another shareholder for no consideration on October 14, 2024.